References
- Lu S. Timely development of vaccines against SARS-CoV-2. Emerg Microbes Infect. 2020;9(1):542–544.
- Pascolo S. Synthetic messenger RNA-Based vaccines: from scorn to hype. Viruses. 2021 Feb 9;13(2):270–282.
- Vaccinations and the impact of COVID-19 – our continuously-updated data for Israel [Internet]. (2021). Available from: https://ourworldindata.org/vaccination-israel-impact.
- WHO. (2020). Global Tuberculosis Report 2019. Available from: https://www.who.int/tb/publications/global_report/en/.
- Bumgarner R. Tuberculosis “global emergency”. Br Med J. 1993;306:1146.
- Xue T, Stavropoulos E, Yang M, et al. RNA encoding the MPT83 antigen induces protective immune responses against Mycobacterium tuberculosis infection. Infect Immun. 2004 Nov;72(11):6324–6329.
- Liu MA. A comparison of plasmid DNA and mRNA as vaccine technologies. Vaccines (Basel). 2019 Apr 24;7(2):37–57.
- Mobed A. DNA Based vaccines against Mycobacterium tuberculosis: recent progress in vaccine development and delivery system. Iran J Immnol. 2020 Dec;17(4):255–274.
- Brazier B, McShane H. Towards new TB vaccines. Semin Immunopathol. 2020 Mar 18;42(3):315–331.
- Whitlow E, Mustafa AS, Hanif SNM. An overview of the development of new vaccines for tuberculosis. Vaccines (Basel). 2020 Oct 5;8(4):586–599.
- Lowrie DB, Tascon RE, Bonato VLD, et al. Therapy of tuberculosis in mice by DNA vaccination. Nature. 1999 Jul;400(6741):269–271.
- Silva CL, Lowrie DB. A single mycobacterial protein (HSP-65) expressed by a transgenic antigen-presenting cell vaccinates mice against tuberculosis. Immunology. 1994 Jun;82(2):244–248.
- Khurana A, Allawadhi P, Khurana I, et al. Role of nanotechnology behind the success of mRNA vaccines for COVID-19. Nano Today. 2021 Jun;38:101142.